3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
464
Lung Neoplasms
147
Melanoma
92
Squamous Cell Carcinoma of Head and Neck
70
Carcinoma, Renal Cell
63
Neoplasms
61
Colorectal Neoplasms
61
Triple Negative Breast Neoplasms
48
Neoplasm Metastasis
48
Parkinson Disease 4, Autosomal Dominant Lewy Body
44
Ovarian Neoplasms
42
Stomach Neoplasms
39
Small Cell Lung Carcinoma
39
Pancreatic Neoplasms
39
Carcinoma, Transitional Cell
38
Breast Neoplasms
38
Head and Neck Neoplasms
34
Uterine Cervical Neoplasms
30
Endometrial Neoplasms
30
Urinary Bladder Neoplasms
26
Esophageal Neoplasms
24
Carcinoma, Hepatocellular
24
Mesothelioma
21
Mesothelioma, Malignant
18
Kidney Neoplasms
15
Prostatic Neoplasms
14
Adenocarcinoma of Lung
14
Carcinoma
13
Colonic Neoplasms
12
Cholangiocarcinoma
12
Interventions
Paclitaxel
3
Carboplatin
3
tremelimumab
1
pembrolizumab
1
necitumumab
1
envafolimab
1
durvalumab
1
anlotinib
1
Nivolumab
1
Gemcitabine
1
Endostatins
1
Drug Therapy
1
Cisplatin
1
Afatinib
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Non-small Cell Lung Cancer
×
pembrolizumab
×
Thoracic
×
Clear all
NCT07221474
2026-05-28
INTerpath-13
Merck Sharp & Dohme LLC
Phase 2
Recruiting
180 enrolled